Zentalis Pharmaceuticals, Inc. cash flow to debt ratio of -316.46% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Zentalis Pharmaceuticals, Inc.'s free cash flow has increased -26.79% from $-171.08M last year to $-125.25M, signaling increasing performance

Zentalis Pharmaceuticals, Inc.'s debt to equity ratio is 0.21, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Zentalis Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.13 last year to 0.21 today, signaling weakened financials

Zentalis Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

Zentalis Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Zentalis Pharmaceuticals, Inc.'s profit margin has increased (-100.00%) in the last year from -245.96% to 0.00%, signaling increasing performance

Zentalis Pharmaceuticals, Inc.'s short-term assets of $253.19M exceed its short-term liabilities of $36.56M

Zentalis Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Zentalis Pharmaceuticals, Inc.'s return on equity of -53.61%, is lower than 15.00%, indicating bad performance

Zentalis Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Zentalis Pharmaceuticals, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Zentalis Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Zentalis Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Zentalis Pharmaceuticals, Inc.'s yearly earnings has increased -17.35% since last year from $-165.84M to $-137.06M, signaling increasing performance

Zentalis Pharmaceuticals, Inc.'s yearly revenue has decreased -100.00% since last year from $67.42M to $0.00, signaling decreasing performance

ROIC -65.38% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Zentalis Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Zentalis Pharmaceuticals, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Zentalis Pharmaceuticals, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Zentalis Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Zentalis Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Zentalis Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Zentalis Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Zentalis Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Zentalis Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Zentalis Pharmaceuticals, Inc. has a price-to-book ratio of 1.55x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Zentalis Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue